JP2022513517A5 - - Google Patents

Info

Publication number
JP2022513517A5
JP2022513517A5 JP2021535249A JP2021535249A JP2022513517A5 JP 2022513517 A5 JP2022513517 A5 JP 2022513517A5 JP 2021535249 A JP2021535249 A JP 2021535249A JP 2021535249 A JP2021535249 A JP 2021535249A JP 2022513517 A5 JP2022513517 A5 JP 2022513517A5
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
group
squamous cell
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513517A (ja
JP7570641B2 (ja
Filing date
Publication date
Priority claimed from EP18306783.4A external-priority patent/EP3669874A1/en
Application filed filed Critical
Publication of JP2022513517A publication Critical patent/JP2022513517A/ja
Publication of JP2022513517A5 publication Critical patent/JP2022513517A5/ja
Application granted granted Critical
Publication of JP7570641B2 publication Critical patent/JP7570641B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535249A 2018-12-20 2019-12-19 癌の処置又は予防において使用する為のキノリン誘導体 Active JP7570641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306783.4A EP3669874A1 (en) 2018-12-20 2018-12-20 Quinoline derivatives for use in the treatment or prevention of cancer
EP18306783.4 2018-12-20
PCT/EP2019/086470 WO2020127839A1 (en) 2018-12-20 2019-12-19 Quinoline derivatives for use in the treatment or prevention of cancer

Publications (3)

Publication Number Publication Date
JP2022513517A JP2022513517A (ja) 2022-02-08
JP2022513517A5 true JP2022513517A5 (https=) 2023-01-31
JP7570641B2 JP7570641B2 (ja) 2024-10-22

Family

ID=65200518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535249A Active JP7570641B2 (ja) 2018-12-20 2019-12-19 癌の処置又は予防において使用する為のキノリン誘導体

Country Status (11)

Country Link
US (1) US20220071985A1 (https=)
EP (2) EP3669874A1 (https=)
JP (1) JP7570641B2 (https=)
KR (2) KR20210136969A (https=)
CN (2) CN113543784A (https=)
AU (1) AU2019408244B2 (https=)
BR (1) BR112021012132A2 (https=)
IL (1) IL284124B2 (https=)
MA (1) MA54512A (https=)
MX (1) MX2021007178A (https=)
WO (1) WO2020127839A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN120152971A (zh) * 2022-11-25 2025-06-13 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN103787992B (zh) * 2014-01-21 2016-04-20 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
JP6474334B2 (ja) 2015-07-30 2019-02-27 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム
PT3429998T (pt) * 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais

Similar Documents

Publication Publication Date Title
JP2022513517A5 (https=)
JP2020517616A5 (https=)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2020514419A5 (https=)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2020508302A5 (https=)
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
JP2022507020A5 (https=)
JP2020515578A5 (https=)
CN120285177A (zh) Hdac抑制剂和pd-1抑制剂的组合疗法
ES2528167T3 (es) Tratamiento de tumores usando anticuerpo anti-L1, específico.
BR112020003646A2 (pt) cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
JP2017186337A5 (https=)
PT2552959T (pt) Anticorpos para muc16 e métodos de utilização dos mesmos
JP2020518669A5 (https=)
JP2021523159A5 (https=)
JP2021522249A5 (https=)
CN101801983A (zh) 调控hsp90活性的三唑化合物
JP2020515571A5 (https=)
JP2019529518A5 (https=)
TWI462908B (zh) 用於治療增生性失調症的化合物
JP2012505916A5 (https=)
JP2020506951A5 (https=)
JP2020534300A5 (https=)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты